Through resolutions 2,617/2022 and 2,560/2022, the National Health Surveillance Agency (Anvisa) decided to take preventive measures against counterfeit batches of the biological product somatropin 20 mg, solution for injection. The drug is used to treat dwarfism and young people with growth hormone production deficiency.
+ Pfizer asks Anvisa for authorization for emergency use of vaccine against Ômicron
According to Anvisa, products with non-original labels or with the printing of batches not recognized by the manufacturers were identified in the Brazilian market. Are they:
Saizen (manufacturer Merck S/A), somatropin, batch AB000569 (Rapid Alert BR/ Counterfeit/208.1.0)
Norditropin (manufacturer Novo Nordisk), somatropin, batch Lk96m38
“For all the complaints received, rapid alerts were issued – urgent information communications to national or international recipients – and preventive measures were published to apprehend, disable and prohibit the commercialization, distribution and use of the products”, informs the agency.
Also according to the Health Surveillance, a health investigation dossier was forwarded to the Federal Police, to help with investigations into allegations of forgery.
Anyone who has somatropin from one of the lots listed above should contact the manufacturer’s customer service to confirm that the product is genuine. The means of contacting the companies are available on the packaging and on the package insert of the products – it is also worth consulting this information on the official websites of the laboratories.
“The company itself must forward the information to Anvisa, in case it suspects counterfeiting”, clarifies the agency.
#Anvisa #warns #fake #batches #medicine #dwarfism